Kiora Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Capital Stock - Narrative (Details)

Capital Stock - Narrative (Details) - USD ($)						3 Months Ended
Capital Stock - Narrative (Details) - USD ($)	Feb. 22, 2023	Feb. 03, 2023	Nov. 17, 2022	Jul. 26, 2022	Jun. 18, 2022	Mar. 31, 2023	Mar. 31, 2022	Aug. 31, 2022
Class of Stock [Line Items]
Holdback shares, term					18 months
Exercise price (in usd per share)				$ 8.00
Proceeds from warrant exercises and sales			$ 3,100,000
Placement agent transaction fees, equal to percentage of gross proceeds from sale			8.00%
Proceeds from issuance of private placement						$ 115,715	$ 0
Proceeds from issuance of common stock						$ 98,960	$ 0
Lincoln Park
Class of Stock [Line Items]
Proceeds from issuance of common stock	$ 100,000
Class A Warrant
Class of Stock [Line Items]
Number of warrants issued to purchase the shares (in shares)				3,925,525
Warrant exercised (in shares)			654,609
Class B Warrant
Class of Stock [Line Items]
Number of warrants issued to purchase the shares (in shares)				3,925,525
Inducement Warrant
Class of Stock [Line Items]
Exercise price (in usd per share)			$ 5.97
Period from issuance that warrant becomes exercisable			6 months
Warrants and rights outstanding, term			18 months
Common Stock
Class of Stock [Line Items]
Period from issuance that warrant becomes exercisable		5 years
Series E Convertible Preferred Stock
Class of Stock [Line Items]
Convertible preferred stock, shares issued upon conversion (in shares)								160,000
Common shares
Class of Stock [Line Items]
Number of warrants issued to purchase the shares (in shares)				98,138
Warrants convertible into common stock				1,504,785
Common Stock
Class of Stock [Line Items]
Equity line of credit (up to)		$ 10,000,000
Common Stock \| Lincoln Park
Class of Stock [Line Items]
Shares issued (in shares)	20,000
Equity line of credit (up to)		$ 10,000,000
Common Stock \| Inducement Warrant
Class of Stock [Line Items]
Number of warrants issued to purchase the shares (in shares)			654,609
Panoptes
Class of Stock [Line Items]
Issuance of common stock from Panoptes holdback shares (in shares)					10,086
Public Offering
Class of Stock [Line Items]
Public offering price per common share, Class A Warrants and Class B Warrants (in usd per share)				$ 8.00
Public offering price per Preferred Share, 5,000 Class A Warrants and 5,000 Class B Warrants (in usd per share)				1,000
Net proceeds				$ 5,300,000
Underwriting discount and commissions				400,000
Underwriting discount and commissions expenses				$ 300,000
Public Offering \| Class A Warrant
Class of Stock [Line Items]
Number of warrants issued to purchase the shares (in shares)				30,095,697
Number of warrants considered for determination of public offering price of preferred shares issued with warrants (shares)				5,000
Public Offering \| Class B Warrant
Class of Stock [Line Items]
Number of warrants issued to purchase the shares (in shares)				30,095,697
Number of warrants considered for determination of public offering price of preferred shares issued with warrants (shares)				5,000
Public Offering \| Series E Convertible Preferred Stock
Class of Stock [Line Items]
Convertible preferred stock, shares issued upon conversion (in shares)				1,280
Public Offering \| Common shares
Class of Stock [Line Items]
Shares issued (in shares)				592,392
Number of warrants issued to purchase the shares (in shares)				160,000
Warrant convertible into common stock basis				2.50%
Private Placement
Class of Stock [Line Items]
Shares issued (in shares)		52,798
Net proceeds		$ 100,000
Class of warrant or right number of warrant issued (in shares)		105,596
Warrants exercisable, anniversary of closing date		6 months
Private Placement \| Common Stock
Class of Stock [Line Items]
Exercise price (in usd per share)		$ 3.538